AU2009204464B2 - Therapeutic inhibitors of PAI-1 function and methods of their use - Google Patents

Therapeutic inhibitors of PAI-1 function and methods of their use Download PDF

Info

Publication number
AU2009204464B2
AU2009204464B2 AU2009204464A AU2009204464A AU2009204464B2 AU 2009204464 B2 AU2009204464 B2 AU 2009204464B2 AU 2009204464 A AU2009204464 A AU 2009204464A AU 2009204464 A AU2009204464 A AU 2009204464A AU 2009204464 B2 AU2009204464 B2 AU 2009204464B2
Authority
AU
Australia
Prior art keywords
pai
seq
subject
promoter
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009204464A
Other languages
English (en)
Other versions
AU2009204464A1 (en
Inventor
Catherine L. Bair
Jonathan Carson
Joan Mazzarelli Sopczynski
Bethany L. Merenick
Richard E. Peterson
Charles C. Reed
Thomas D. Reed
Elena Tasheva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Precigen Inc
Original Assignee
Intrexon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrexon Corp filed Critical Intrexon Corp
Publication of AU2009204464A1 publication Critical patent/AU2009204464A1/en
Application granted granted Critical
Publication of AU2009204464B2 publication Critical patent/AU2009204464B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8132—Plasminogen activator inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2451—Glucanases acting on alpha-1,6-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01099—Arabinan endo-1,5-alpha-L-arabinosidase (3.2.1.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2009204464A 2008-01-09 2009-01-09 Therapeutic inhibitors of PAI-1 function and methods of their use Ceased AU2009204464B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2013708P 2008-01-09 2008-01-09
US61/020,137 2008-01-09
US8064008P 2008-07-14 2008-07-14
US61/080,640 2008-07-14
PCT/US2009/000155 WO2009089059A2 (en) 2008-01-09 2009-01-09 Therapeutic inhibitors of pai-1 function methods of their use

Publications (2)

Publication Number Publication Date
AU2009204464A1 AU2009204464A1 (en) 2009-07-16
AU2009204464B2 true AU2009204464B2 (en) 2014-12-04

Family

ID=40853701

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009204464A Ceased AU2009204464B2 (en) 2008-01-09 2009-01-09 Therapeutic inhibitors of PAI-1 function and methods of their use

Country Status (12)

Country Link
US (2) US8431363B2 (enExample)
EP (1) EP2242501A4 (enExample)
JP (2) JP2011509093A (enExample)
KR (1) KR101712208B1 (enExample)
CN (1) CN102123721A (enExample)
AU (1) AU2009204464B2 (enExample)
BR (1) BRPI0906867A2 (enExample)
CA (1) CA2711878A1 (enExample)
IL (1) IL206891A0 (enExample)
MX (1) MX2010007586A (enExample)
RU (1) RU2010133847A (enExample)
WO (1) WO2009089059A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8431363B2 (en) 2008-01-09 2013-04-30 Intrexon Corporation Polynucleotides encoding therapeutic inhibitors of PAI-1
ES2906750T3 (es) * 2010-05-12 2022-04-20 Prokidney Células renales bioactivas
CN104271593B (zh) 2012-05-01 2018-01-16 富士胶片株式会社 多能干细胞的培养方法及该方法中使用的多肽
CN103421781B (zh) * 2012-07-04 2014-12-31 华中农业大学 猪肌肉组织特异性表达基因myf6启动子及应用
CA2941958A1 (en) * 2013-12-10 2015-06-18 F. Hoffmann-La Roche Ag Use of the binding domain of a subunit of a multi-subunit structure for targeted delivery of pharmaceutically active entities to the multi-subunit structure
TWI677348B (zh) 2016-12-15 2019-11-21 大陸商深圳瑞健生命科學研究院有限公司 一種改善心臟病變的方法
TWI750189B (zh) * 2016-12-15 2021-12-21 大陸商深圳瑞健生命科學研究院有限公司 一種治療冠狀動脈粥樣硬化及其併發症的方法
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
JP7604376B2 (ja) 2018-12-28 2024-12-23 バーテックス ファーマシューティカルズ インコーポレイテッド 改変ウロキナーゼ型プラスミノゲンアクティベータポリペプチドおよび使用方法
CN119656313B (zh) * 2024-12-13 2026-02-17 四川大学华西医院 Serpine1基因作为靶点在制备预防或治疗心肌纤维化药物中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639726A (en) * 1994-09-30 1997-06-17 The Regents Of The University Of Michigan Peptide mediated enhancement of thrombolysis methods and compositions
DE10053251A1 (de) * 2000-10-26 2002-05-08 Boehringer Ingelheim Pharma Epitope von PAI-1
WO2003095476A2 (en) * 2002-05-08 2003-11-20 Thrombotech Ltd. PEPTIDES FOR REGULATION OF UROKINASE (uPA) AND TISSUE TYPE (tPA) PLASMINOGEN ACTIVATOR AND METHOD OF OPTIMIZING THERAPEUTIC EFFICACY

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2385703A1 (en) * 1999-10-07 2001-04-12 Human Genome Sciences, Inc. Plasminogen-like polynucleotides, polypeptides, and antibodies
US20030199463A1 (en) 2002-04-23 2003-10-23 Silviu Itescu DNA enzyme to inhibit plasminogen activator inhibitor-1
JP2006507297A (ja) * 2002-05-13 2006-03-02 チルドレンズ・ホスピタル・ロサンジェルス ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防
US7241613B1 (en) * 2002-06-05 2007-07-10 Oscient Pharmaceuticals Corporation Identification of Candida cell surface proteins and their uses
US20080050808A1 (en) * 2002-10-09 2008-02-28 Reed Thomas D DNA modular cloning vector plasmids and methods for their use
US7785871B2 (en) * 2002-10-09 2010-08-31 Intrexon Corporation DNA cloning vector plasmids and methods for their use
US7071295B2 (en) * 2002-12-02 2006-07-04 Intrexon Corporation Signal for targeting molecules to the sarco(endo)plasmic reticulum
WO2004052856A1 (en) 2002-12-10 2004-06-24 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
ES2603062T3 (es) 2004-05-18 2017-02-23 Intrexon Corporation Métodos de ensamblaje dinámico de vectores para la clonación de ADN de vectores plasmídicos
WO2007048103A2 (en) 2006-10-18 2007-04-26 Intrexon Corporation Pkd ligands and polynucleotides encoding pkd ligands
US8153598B2 (en) * 2005-10-19 2012-04-10 Intrexon Corporation PKD ligands and polynucleotides encoding PKD ligands
US7943732B2 (en) * 2006-06-05 2011-05-17 Intrexon Corporation AKT ligands and polynucleotides encoding AKT ligands
US8993263B2 (en) * 2006-08-07 2015-03-31 Intrexon Corporation PKA ligands and polynucleotides encoding PKA ligands
US8999666B2 (en) * 2006-08-09 2015-04-07 Intrexon Corporation PKC ligands and polynucleotides encoding PKC ligands
US8729225B2 (en) * 2006-11-13 2014-05-20 Intrexon Corporation Glycogen synthase kinase heteropolyligand polypeptide
US8283445B2 (en) * 2006-11-13 2012-10-09 Intrexon Corporation Extracellular-signal-regulated-kinase (ERK) heteropolyligand polypeptide
US7705122B2 (en) * 2006-12-04 2010-04-27 Intrexon Corporation mTOR ligands and polynucleotides encoding mTOR ligands
ES2390156T3 (es) 2007-03-27 2012-11-07 Intrexon Corporation Ligandos de MEK y polinucleótidos que codifican ligandos de MEK
EP2150273A4 (en) * 2007-04-27 2010-11-17 Univ Toledo MODIFIED PLASMINOGEN ACTIVATOR INHIBITOR MOLECULE AND METHODS OF USE
US8431363B2 (en) 2008-01-09 2013-04-30 Intrexon Corporation Polynucleotides encoding therapeutic inhibitors of PAI-1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639726A (en) * 1994-09-30 1997-06-17 The Regents Of The University Of Michigan Peptide mediated enhancement of thrombolysis methods and compositions
DE10053251A1 (de) * 2000-10-26 2002-05-08 Boehringer Ingelheim Pharma Epitope von PAI-1
WO2003095476A2 (en) * 2002-05-08 2003-11-20 Thrombotech Ltd. PEPTIDES FOR REGULATION OF UROKINASE (uPA) AND TISSUE TYPE (tPA) PLASMINOGEN ACTIVATOR AND METHOD OF OPTIMIZING THERAPEUTIC EFFICACY

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Eitzman, D.T et al, The Journal of Clinical Investigation (1995), Volume 95, pages 2416-2420. *

Also Published As

Publication number Publication date
EP2242501A4 (en) 2011-10-19
JP2012135307A (ja) 2012-07-19
EP2242501A2 (en) 2010-10-27
WO2009089059A3 (en) 2009-09-24
AU2009204464A1 (en) 2009-07-16
IL206891A0 (en) 2010-12-30
US8828686B2 (en) 2014-09-09
KR20100129271A (ko) 2010-12-08
US8431363B2 (en) 2013-04-30
KR101712208B1 (ko) 2017-03-03
CN102123721A (zh) 2011-07-13
CA2711878A1 (en) 2009-07-16
JP2011509093A (ja) 2011-03-24
WO2009089059A2 (en) 2009-07-16
BRPI0906867A2 (pt) 2019-09-24
MX2010007586A (es) 2011-02-22
US20130267022A1 (en) 2013-10-10
US20110055940A1 (en) 2011-03-03
RU2010133847A (ru) 2012-05-20

Similar Documents

Publication Publication Date Title
US8828686B2 (en) Polynucleotides encoding therapeutic inhibitors of PAI-1
KR100188302B1 (ko) 활성화피브린용해성과항-혈전성단백질
Nara et al. Elastase inhibitor elafin is a new type of proteinase inhibitor which has a transglutaminase-mediated anchoring sequence termed “cementoin”
JP4451514B2 (ja) 血液凝固第ｖｉｉ因子改変体
US6201104B1 (en) Angiogenesis—inhibiting protein binding peptides and proteins and methods of use
CZ20031718A3 (cs) Polypeptidická proteáza štěpící von Willebrandův faktor (vWF), nukleová kyselina kódující tento polypeptid a použití tohoto polypeptidu
JPH11509187A (ja) 内皮細胞増殖の調節
CA2379152A1 (en) Novel angiopoietin materials and methods
JPH05508664A (ja) リン脂質標的血栓溶解剤
Zani et al. Protease inhibitors derived from elafin and SLPI and engineered to have enhanced specificity towards neutrophil serine proteases
JPH04503761A (ja) Ｐａｉ―２の変異体
WO2001093897A2 (en) Angiostatin and endostatin binding proteins and methods of use
JPH04505554A (ja) 可溶性トロンボモジュリン類似体
JP2002524076A (ja) ＫｕｎｉｔｚドメインポリペプチドＺＫＵＮ６
EP1088069B1 (en) Angiostatin-binding protein
KR20190112763A (ko) 인자 ix 융합 단백질 및 이의 제조 및 사용 방법
JP2013517782A (ja) 因子ｖｉｉ融合ポリペプチド
CA2555510A1 (en) Antiplasmin cleaving enzyme
CA2924836A1 (en) Methods and compositions related to mutant kunitz domain i of tfpi-2
US7223730B2 (en) Antithrombosis enzyme from the snake venom of agkistrodon acutus
JP2002085059A (ja) 新規なｔｓｐ１ドメイン含有ポリペプチド
JPH04505252A (ja) Ｅ．ｃｏｌｉにおける機能的ヒトプラスミノーゲン活性化因子阻害剤（ＰＡＩ―１）の高水準発現
JP2003174890A (ja) 新規セリンプロテアーゼ阻害蛋白質ｍｔ００３９
JPH09124700A (ja) 新規プロテアーゼインヒビターおよびその製造方法、エラスターゼが関与する疾患の治療剤
Pintucci The cardiovascular effects of proteolysis of high molecular weight basic fibroblast growth factor by inflammatory serine proteases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired